Events

EU - Webinar: Maximizing the Impact of Horizon project results
DEC
Tue
03
10:30 - 12:00

This was 11 months ago

Location

Online

Programmes
Horizon Europe

The European IP Helpdesk, together with the European Innovation Council and SMEs Executive Agency, organise a webinar on maximising the impact of horizon project results.

Learn more about exploitation of Intellectual Property (IP) rights in Horizon projects. This webinar gives an overall view of the creation and the development of IP rights both during and after the duration of an Horizon project. The most common planning mistakes will be analysed and some practical tips will be given.

After the training, participants should have a better understanding of the following:

  • The IP in the Consortium Agreements: a particular regard to the results of the research.
  • Which are the best means to maximize the value of your IP?
  • Assessing your IP: How can you estimate the value of your IP?
  • Which are the best exploitation strategies and business plans for entering the market?
  • Reap the rewards of your IP: taking a closer look at the different forms of licensing.


More information and registration here

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.